WAM
CARM

Weiss Asset Management’s Carisma Therapeutics CARM Stock Holding History

Weiss Asset Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,618
Closed -$54K – 362
2019
Q1 		$54K Hold
2,618
– – ﹤0.01% 287
2018
Q4 		$74K Buy
+2,618
New +$83.5K 0.01% 410

Other funds holding CARM

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Weiss Asset Management's CARM Position: Q2 2019 in Review

Weiss Asset Management sold out of Carisma Therapeutics (CARM) in Q2 2019, closing a stake of 2,618 shares — an estimated $54K sold.

Weiss Asset Management first reported a position in CARM in Q4 2018 and held it in 2 quarters. The position peaked at $74K in Q4 2018. 43 funds tracked by Wall St. Rank hold CARM as of Q2 2019.

  • Weiss Asset Management reported no remaining Carisma Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Weiss Asset Management sold 2,618 Carisma Therapeutics shares in Q2 2019, an estimated $54K.
  • Weiss Asset Management first reported a position in Carisma Therapeutics in Q4 2018 and held it in 2 quarters.
  • Weiss Asset Management's Carisma Therapeutics position peaked at $74K in Q4 2018.
  • 43 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2019.

Based on Weiss Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.